MedTrace Logo

Continuous Infusion of Terlipressin in Septic Shock

NCT00481572 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2008-02-29

No results posted yet for this study

Summary

The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.

Conditions

  • Septic Shock

Interventions

DRUG

Terlipressin

continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs

DRUG

Vasopressin

continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs

DRUG

Norepinephrine

titrated norepinephrine over a period of 48 hrs

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Andrea Morelli, MD · Departement of Anesthesiology and Intensive Care of the University of Rome "La Sapienza"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481572 on ClinicalTrials.gov